Voices from the IPO Class of 2024: What's Next?
February 10, 2025
Astor
2024 saw a modest uptick compared to the past few years in successful biotech IPOs. In this panel, executives who survived the IPO gauntlet will share the lessons learned during the IPO process and their new world post-IPO. They’ll provide insights as to what investors are looking for, what to expect after trading begins and what 2025 may hold for the next generation of biotech IPOs.
Moderator
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}